Free to Breathe
1 Point Place #200
Madison, WI 53719
TRAIN Inventory Profile
- Research Portfolio
- Key Accomplishments
- Ask Us About
- EXPAND ALL
The mission of Free to Breathe is to ensure that surviving lung cancer is the expectation and note the exception. At this point, the five-year survival rate for lung cancer is about 17 percent and needs drastic improvement.
One reason for poor survival and outcomes in lung cancer is the advanced stage at which it is often diagnosed. Free to Breathe is strategically working on programs to increase awareness of symptoms and encourage visits for lung cancer screening.
Free to Breathe has created new patient education materials encouraging more open discussions with doctors and stressing the importance of patents having their tumor tested for biomarkers. Through a 16-center member consortium, Free to Breathe is hoping to better understand the driver mutations in lung cancer and assist patients in finding treatments more targeted for their type of disease.
New strategic approaches are soon to be implemented.
Lung cancer metastasis is a critical problem. Often the brain is the first location, thereby leading to very poor outcomes for patients. Free to Breathe is sponsoring the Metastasis Grant to better understand metastasis in lung cancer patients and seek treatment to better stop the spread of lung cancer to other parts of the body.
Due to the low enrollment rate in clinical trials, Free to Breathe is sponsoring an Accelerate Clinical Trial Grant in order to have researchers identify and scientifically test new solutions, interventions or strategies through developing pilot projects. The funded proposals must include a clear vision about how the pilot project, if successful, can be expanded to other institutions for validation of the intervention or strategy. Free to Breathe’s intent is to fund projects that will be reproducible and implementable to a wider community.
Fiscal year 2015, year ending 12/31/15, Annual Report 2015 (under final review)
- Revenue: $4.4M
- Assets: $2.9M
- Grants: $1.4M
- Gifts Received: $300,000
- Total Expenditures: $4.6M
Free to Breathe has funded over $5 million in research over a very short period of time. We are in the process of putting together a summary article about the accomplishments/outcomes of this important research. We plan to raise additional funds in order to increase the number of grants we provide to key researchers in the field.
Free to Breathe started as an organization to bring attention to the fact that so many women were suffering from lung cancer. However, after a few short years as Women Against Lung Cancer, the organization changed its name to National Lung Cancer Partnership to be more inclusive of all people affected by lung cancer.
Our first Lung Cancer Advocacy Summit was held in 2008 and our annual summit has now become a much larger Leadership Conference to help patients understand advances in the lung cancer space and to assist them in becoming advocates for lung cancer funding and research.
Given that Free to Breathe started an event series with 30 events that engaged more than 29,000 participants in 2009, the organization officially changed its name from the National Lung Cancer Partnership to Free to Breathe to bring a more cohesive approach to its mission.
In 2012 the Board launched a bold new vision to double survival of lung cancer by 2022.
Free to Breathe is governed by a board of directors.
- Chief Operating Officer, Sherie Reinders, firstname.lastname@example.org, 608-828-8842
- Director of Scientific Education and Research, Mary Henningfield, email@example.com, 608-828-8831
- Marketing and Communications Director, Sara Ifert, firstname.lastname@example.org 608-828-8836
- Director Business Development, Allison Formal email@example.com, 253-250-9711
- National Events Director, Taryn Dwan, firstname.lastname@example.org, 908-803-5254
- VP Finance, Amy Hall, email@example.com 608-828-8843
Ask Us About
- Building research collaborations
- Clinical trial design and recruitment
- Development of tools and resources
- Facilitating patient engagement in the R&D process
- Partnering with industry
- Social media and communications
- Strategic planning